Should we operate on asymptomatic patients with severe mitral regurgitation?
Grayburn
Paul A
PA
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas.
D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control; D006348:Cardiac Surgical Procedures / Q000009:adverse effects / Q000401:mortality; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008943:Mitral Valve / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D018579:Patient Selection; D018570:Risk Assessment; D012720:Severity of Illness Index; D013318:Stroke Volume; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D016277:Ventricular Function, Left